Depression News and Research

Latest Depression News and Research

Perception, rather than actual sleep quality may predict postpartum mood disturbances in new mothers

A study of healthy new mothers in the April 1 issue of the journal Sleep found that the perception of poor sleep and the conscious awareness of its impact on daytime functioning might be stronger predictors of immediate postpartum mood disturbances than actual sleep quality and quantity.

1 Apr 2010

Metabolon awarded U.S. patents for metabolomics methods

Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, announced today the grant of US Patent 7,682,783 and US Patent 7,682,784 entitled "Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics". The USPTO awarded the patents to Metabolon on March 23, 2010. The issued claims in the new patents are for uses of metabolomics to identify diagnostic biomarkers for depression and schizophrenia by profiling classes of metabolites in a sample.

1 Apr 2010

Structured and supervised exercise can prevent postnatal depression, says study

Postnatal depression (PND) or baby blues are a recognized entity with millions of mothers suffering from it in varying degrees. It affects 13% of the new mothers usually within the first 3 months after the birth of the baby.

1 Apr 2010

Vidazorb probiotic supplements could minimize severity of IBS symptoms

April is Irritable Bowel Syndrome (IBS) Awareness Month. IBS is a chronic condition affecting between 15 and 20 percent of all adults in the Western world. However, IBS is difficult to identify due to the numerous symptoms associated with it. Almost 40 percent of IBS sufferers report symptoms severe and frequent enough to disrupt their daily lives, making it is a serious issue—one to which Vidazorb® probiotic supplements may offer some relief.

31 Mar 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

Updated Support Partners Program helps people with depression to build support group

The Support Partners Program offered by Lilly USA is introducing several updated educational resources for people with depression and the people who care for them.

31 Mar 2010

Bright light therapy box for SAD, depression, bipolar disorder and sleep problems

Alaska Northern Lights manufactures a bright light therapy box that aids in treating chronic health problems such as seasonal affective disorder (SAD), depression, bipolar disorder and sleep problems. Sufferers of SAD, a form of clinical depression, include up to 25 percent of those living in northern latitudes who experience varying degrees of SAD during winter months when there is less natural light. Night shift workers are also susceptible to SAD which affects over one third of the population, or about 10.8 million Americans.

31 Mar 2010

New clues may help explain why some people are more susceptible to stress than others

UT Southwestern Medical Center researchers have found new clues that might help explain why some people are more susceptible to stress than others.

31 Mar 2010

PMDD often misdiagnosed as major depression or other mood disorder

As science slowly, but continually, unravels the causes of disorders, it increasingly teases apart biological threads that, when spooled together, begin to take on the warp and weft of separate disorders.

31 Mar 2010

NeurOp and Bristol-Myers Squibb announce drug discovery collaboration

NeurOp Corporation today announced a collaboration with Bristol-Myers Squibb Company (NYSE: BMY) focused upon the development of NeurOp's proprietary small molecules for use in the treatment of major depression and other central nervous system disorders.

31 Mar 2010

Depomed licensee submits DM-1796 NDA for management of PHN

Depomed, Inc. today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

31 Mar 2010

Close-ups on how the health overhaul gives and takes away

"An association representing 300 large corporations urged President Obama and Congress on Monday to repeal a provision of the health care overhaul that prompted AT&T, Caterpillar and other companies to announce substantial charges for the current quarter."

31 Mar 2010

Neuroscientists prevent memory loss in fruit flies by blocking activity of PI3 kinase signaling protein

By blocking the cellular signaling activity of a protein, a team of neuroscientists at Cold Spring Harbor Laboratory (CSHL) has prevented memory loss in fruit flies caused by brain plaques similar to those thought to cause Alzheimer's disease in humans. The study also resolves a long-standing controversy about the role of this protein, PI3 kinase, which was previously thought to have a protective function against the disease.

30 Mar 2010

Fecal incontinence: Sacral nerve stimulation along with Medtronic InterStim Therapy promising

Data published in the March issue of the Annals of Surgery show that investigational use of sacral nerve stimulation with Medtronic InterStim® Therapy reduces fecal incontinent episodes and increases quality of life in patients with the condition. The 120-patient, multi-center study - the largest trial of its kind in the world and the first such trial in North America - examined the efficacy of InterStim Therapy in patients with chronic fecal incontinence who had failed or were not candidates for more conservative treatments.

30 Mar 2010

Decision Resources: Only 52.2% of first-line Alzheimer's disease patients prescribed AChEI

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that while approximately 70 percent of surveyed physicians' newly diagnosed patients have mild-to-moderate Alzheimer's disease, only 52.2 percent of first-line patients are prescribed an acetylcholinesterase inhibitor.

30 Mar 2010

APP adds eClinicalWorks' EMR system to CI Program

In its continuing efforts to enhance patient outcomes and create efficiency in a challenging economic and regulatory climate, Advocate Physician Partners, has added the power of an electronic medical record system to its award-winning Clinical Integration Program. APP, the largest network of independent physicians in the Midwest, is partnering with eClinicalWorks® in one of the biggest EMR implementations in the country.

29 Mar 2010

Workforce pipeline to help address disparities in mental health services in Massachusetts

Supporting clinical training programs that develop language skills and cultural competence and forgiving educational loans for psychology graduates who have this kind of training can help meet the critical need for mental health providers to care for Latinos and other underserved populations, said leaders of Massachusetts School of Professional Psychology, who spoke at the state Health Disparities Council meeting earlier this week.

29 Mar 2010

Seniors with diabetes and dementia more likely to fall into Medicare Part D prescription drug plan

Among seniors, women and patients with diabetes and dementia are the most likely to fall into the Medicare Part D prescription drug plan "donut hole" - the gap occurring after beneficiaries reach their annual coverage limit and before catastrophic coverage kicks in - according to new research published online in the Journal of General Internal Medicine.

29 Mar 2010

Cortex signs agreement to sell certain AMPAKINE compounds to Biovail

Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL in which Biovail acquired certain AMPAKINE compounds and the rights to the patent filing for respiratory depression and vaso-occlusive crises associated with sickle cell disease.

29 Mar 2010

Infrafrontier project expands to include six new partners

Helmholtz Zentrum M-nchen today announced that the Infrafrontier project, funded by the European Union, has been expanded to include six partners from Canada, the Czech Republic, Austria, France and Italy. The new partners will join the effort of the other 22 members of Infrafrontier in building up an international research infrastructure to improve open access to high-quality mouse models.

27 Mar 2010

Depression News and Research

Latest Depression News and Research

Perception, rather than actual sleep quality may predict postpartum mood disturbances in new mothers

Metabolon awarded U.S. patents for metabolomics methods

Structured and supervised exercise can prevent postnatal depression, says study

Vidazorb probiotic supplements could minimize severity of IBS symptoms

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Updated Support Partners Program helps people with depression to build support group

Bright light therapy box for SAD, depression, bipolar disorder and sleep problems

New clues may help explain why some people are more susceptible to stress than others

PMDD often misdiagnosed as major depression or other mood disorder

NeurOp and Bristol-Myers Squibb announce drug discovery collaboration

Depomed licensee submits DM-1796 NDA for management of PHN

Close-ups on how the health overhaul gives and takes away

Neuroscientists prevent memory loss in fruit flies by blocking activity of PI3 kinase signaling protein

Fecal incontinence: Sacral nerve stimulation along with Medtronic InterStim Therapy promising

Decision Resources: Only 52.2% of first-line Alzheimer's disease patients prescribed AChEI

APP adds eClinicalWorks' EMR system to CI Program

Workforce pipeline to help address disparities in mental health services in Massachusetts

Seniors with diabetes and dementia more likely to fall into Medicare Part D prescription drug plan

Cortex signs agreement to sell certain AMPAKINE compounds to Biovail

Infrafrontier project expands to include six new partners

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Depression News and Research

Latest Depression News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in